GSK - Hikma to acquire GlaxoSmithKline assets in Egypt and Tunisia

Hikma Pharmaceuticals (HKMPF) has confirmed that it is in talks with GlaxoSmithKline S.A.E. (GSK SAE), the listed Egyptian subsidiary within the GlaxoSmithKline (GSK), for a potential acquisition of GSK’s assets in Egypt and Tunisia.Noting disclosure made today to the Egyptian Exchange by GlaxoSmithKline S.A.E., Hikma says that it has entered into a non-binding term sheet with GSK for pharma giant’s pharmaceutical and consumer commercialization and manufacturing business in Egypt and pharmaceutical business in Tunisia.In addition to receiving GSK SAE’s board consent, “the Proposed Transaction is subject to a number of conditions, including the finalization of definitive and legally binding documents and the completion of due diligence by Hikma,” the statement from Hikma said.

For further details see:

Hikma to acquire GlaxoSmithKline assets in Egypt and Tunisia